Registry Study for Talimogene Laherparepvec

Clinical trial NCT02173171 · COMPLETED

Trial details

NCT number: NCT02173171
Sponsor: Amgen
Status: COMPLETED
Study type: OBSERVATIONAL

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial

Start date: 2010-04-27
Primary completion: 2021-09-23
Enrollment: 185

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.